Genetic evaluation of short stature

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3080-3092

  Dauber, Andrew ^a,b   Rosenfeld, Ron G ^c   Hirschhorn, Joel N ^a,b,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PROLACTIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; SOMATOMEDIN C; THYROTROPIN;

BODY HEIGHT; BONE DYSPLASIA; BONE RADIOGRAPHY; CCDC8 GENE; CDKN1C GENE; CHILDHOOD DISEASE; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CUL7 GENE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HORMONE DEFICIENCY; HORMONE RESISTANCE; HORMONE SYNTHESIS; HUMAN; HYPOPITUITARISM; IDIOPATHIC SHORT STATURE; INSULIN LIKE GROWTH FACTOR DEFICIENCY; INTRAUTERINE GROWTH RETARDATION; MOLECULAR PATHOLOGY; MONOGENIC DISORDER; MUTATIONAL ANALYSIS; NPR2 GENE; OBSL1 GENE; PATIENT SELECTION; PROTEIN EXPRESSION; PTPN11 GENE; REVIEW; SHORT STATURE; SHOX GENE; ALGORITHM; ENDOCRINOLOGY; GENETICS; GENOMICS; GROWTH DISORDERS; PRACTICE GUIDELINE; STANDARDS;

ALGORITHMS; BODY HEIGHT; ENDOCRINOLOGY; GENETIC TESTING; GENOMICS; GROWTH DISORDERS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84907190302     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1506     Document Type: Review

References (97)

1. Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008; 93: 4210-4217.
2. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007; 92: 804-810.
3. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of theGHResearch Society. GH Research Society. J Clin Endocrinol Metab. 2000; 85: 3990-3993.
4. Ahmed ML, Allen AD, Sharma A, Macfarlane JA, Dunger DB. Evaluation of a district growth screening programme: the Oxford Growth Study. Arch Dis Child. 1993; 69: 361-365.
5. Grote FK, Oostdijk W, De Muinck Keizer-Schrama SM, et al. The diagnostic work up of growth failure in secondary health care; an evaluation of consensus guidelines. BMC Pediatr. 2008; 8: 21.
6. Voss LD, Mulligan J, Betts PR, Wilkin TJ. Poor growth in school entrants as an index of organic disease: the Wessex growth study. BMJ. 1992; 305: 1400-1402.
7. Green AA, MacFarlane JA. Method for the earlier recognition of abnormal stature. Arch Dis Child. 1983; 58: 535-537.
8. Grimberg A, Kutikov JK, Cucchiara AJ. Sex differences in patients referred for evaluation of poor growth. J Pediatr. 2005; 146: 212-216.
9. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994; 125: 29-35.
10. Sisley S, Trujillo MV, Khoury J, Backeljauw P. Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic short children. J Pediatr. 2013; 163: 1045-1051.
11. Tauber M, Moulin P, Pienkowski C, Jouret B, Rochiccioli P. Growth hormone (GH) retesting and auxological data in 131 GHdeficient patients after completion of treatment. J Clin Endocrinol Metab. 1997; 82: 352-356.
12. Marin G, Domené HM, Barnes KM, Blackwell BJ, Cassorla FG, Cutler GB Jr. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab. 1994; 79: 537-541.
13. Wit JM, Kiess W, Mullis P. Genetic evaluation of short stature. Best Pract Res Clin Endocrinol Metab. 2011; 25: 1-17.
14. Hirschhorn JN, Lettre G. Progress in genome-wide association studies of human height. Horm Res. 2009; 71(suppl 2): 5-13.
15. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010; 467: 832-838.
16. Hemani G, Yang J, Vinkhuyzen A, et al. Inference of the genetic architecture underlying BMI and height with the use of 20,240 sibling pairs. Am J Hum Genet. 2013; 93: 865-875.
17. Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010; 42: 565-569.
18. Chan Y, Holmen OL, Dauber A, et al. Common variants show predicted polygenic effects on height in the tails of the distribution, except in extremely short individuals. PLoS Genet. 2011; 7: e1002439.
19. Olney RC, Bükülmez H, Bartels CF, et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab. 2006; 91: 1229-1232.
20. Dauber A, Yu Y, Turchin MC, et al. Genome-wide association of copy-number variation reveals an association between short stature and the presence of low-frequency genomic deletions. Am J Hum Genet. 2011; 89: 751-759.
21. van Duyvenvoorde HA, Lui JC, Kant SG, et al. Copy number variants in patients with short stature. Eur J Hum Genet. 2014; 22: 602-609.
22. Zahnleiter D, Uebe S, Ekici AB, et al. Rare copy number variants are a common cause of short stature. PLoS Genet. 2013; 9: e1003365.
23. McQuillan R, Eklund N, Pirastu N, et al. Evidence of inbreeding depression on human height. PLoS Genet. 2012; 8: e1002655.
24. Lepri FR, Scavelli R, Digilio MC, et al. Diagnosis of Noonan syndrome and related disorders using target next generation sequencing. BMC Med Genet. 2014; 15: 14.
25. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL. Children born small for gestational age: do they catch up? Pediatr Res. 1995; 38: 267-271.
26. Karlberg J, Albertsson-Wikland K. Growth in full-Term small-forgestational-Age infants: from birth to final height. Pediatr Res. 1995; 38: 733-739.
27. Saal HM. Russell-Silver syndrome. GeneReviews [Internet]. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. Seattle, WA: University of Washington, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK1324/. Published November 2, 2002. Updated June 2, 2011.
28. Netchine I, Rossignol S, DufourgMN,et al. 11p15 imprinting center region 1 loss of methylation is acommonand specific cause of typical Russell-Silver syndrome: clinical scoring system and epigenetic-phenotypic correlations. J Clin Endocrinol Metab. 2007; 92: 3148-3154.
29. Brioude F, Oliver-Petit I, Blaise A, et al. CDKN1C mutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome. J Med Genet. 2013; 50: 823-830.
30. Arboleda VA, Lee H, Parnaik R, et al. Mutations in the PCNAbinding domain of CDKN1C cause IMAGe syndrome. Nat Genet. 2012; 44: 788-792.
31. Akawi NA, Ali BR, Hamamy H, Al-Hadidy A, Al-Gazali L. Is autosomal recessive Silver-Russell syndrome a separate entity or is it part of the 3-M syndrome spectrum? Am J Med Genet A. 2011; 155A: 1236-1245.
32. Clayton PE, Hanson D, Magee L, et al. Exploring the spectrum of 3-M syndrome, a primordial short stature disorder of disrupted ubiquitination. Clin Endocrinol (Oxf). 2012; 77: 335-342.
33. Al-Dosari MS, Al-Shammari M, Shaheen R, et al. 3M syndrome: an easily recognizable yet underdiagnosed cause of proportionate short stature. J Pediatr. 2012; 161: 139-145.e1.
34. Dauber A, Stoler J, Hechter E, Safer J, Hirschhorn JN. Whole exome sequencing reveals a novel mutation in CUL7 in a patient with an undiagnosed growth disorder. J Pediatr. 2013; 162: 202-204.e1.
35. Guo MH, Shen Y, Walvoord EC, et al. Whole exome sequencing to identify genetic causes of short stature [published online June 20, 2014]. Horm Res Paediatr. doi: 10.1159/000360857.
36. Klingseisen A, Jackson AP. Mechanisms and pathways of growth failure in primordial dwarfism. Genes Dev. 2011; 25: 2011-2024.
37. Seaver LH, Irons M. ACMG practice guideline: genetic evaluation of short stature. Genet Med. 2009; 11: 465-470.
38. David A, Hwa V, Metherell LA, et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev. 2011; 32: 472-497.
39. Mullis PE. Genetic control of growth. Eur J Endocrinol. 2005; 152: 11-31.
40. Alatzoglou KS, Turton JP, Kelberman D, et al. Expanding the spectrum of mutations inGH1and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab. 2009; 94: 3191-3199.
41. Alatzoglou KS,WebbEA, Le Tissier P, DattaniMT.Isolated growth hormone deficiency (Ghd) in childhood and adolescence: recent advances. Endocr Rev. 2014; 35: 376-432.
42. Laumonnier F, Ronce N, Hamel BC, et al. Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am J Hum Genet. 2002; 71: 1450-1455.
43. Burkitt Wright EM, Perveen R, Clayton PE, et al. X-linked isolated growth hormone deficiency: expanding the phenotypic spectrum of SOX3 polyalanine tract expansions. Clin Dysmorphol. 2009; 18: 218-221.
44. Pantel J, Legendre M, Nivot S, et al. Recessive isolated growth hormone deficiency and mutations in the ghrelin receptor. J Clin Endocrinol Metab. 2009; 94: 4334-4341.
45. Pfäffle R, Klammt J. Pituitary transcription factors in the aetiology of combined pituitary hormone deficiency. Best Pract Res Clin Endocrinol Metab. 2011; 25: 43-60.
46. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone-A new inborn error of metabolism? Isr J Med Sci. 1966; 2: 152-155.
47. Amselem S, Duquesnoy P, Attree O, et al. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med. 1989; 321: 989-995.
48. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-Aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011; 3: 70ra13.
49. Guevara-Aguirre J, Rosenbloom AL, Guevara-Aguirre M, et al. Effects of heterozygosity for the E180 splice mutation causing growth hormone receptor deficiency in Ecuador on IGF-I, IGFBP-3, and stature. Growth Horm IGF Res. 2007; 17: 261-264.
50. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev. 1994; 15: 369-390.
51. Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003; 349: 1139-1147.
52. Hwa V, Nadeau K, Wit JM, Rosenfeld RG. STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab. 2011; 25: 61-75.
53. Domené HM, Hwa V, Argente J, et al. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res. 2009; 72: 129-141.
54. Woods KA, Camacho-Hübner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996; 335: 1363-1367.
55. Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003; 349: 2211-2222.
56. Warman ML, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011; 155A: 943-968.
57. Kant SG, Grote F, de Ru MH, et al. Radiographic evaluation of children with growth disorders. Horm Res. 2007; 68: 310-315.
58. Veeramani AK, Higgins P, Butler S, et al. Diagnostic use of skeletal survey in suspected skeletal dysplasia. J Clin Res Pediatr Endocrinol. 2009; 1: 270-274.
59. Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997; 16: 54-63.
60. Binder G, Ranke MB, Martin DD. Auxology is a valuable instrument for the clinical diagnosis of SHOX haploinsufficiency in school-Age children with unexplained short stature. J Clin Endocrinol Metab. 2003; 88: 4891-4896.
61. Chen J, Wildhardt G, Zhong Z, et al. Enhancer deletions of the SHOX gene as a frequent cause of short stature: the essential role of a 250 kb downstream regulatory domain. J Med Genet. 2009; 46: 834-839.
62. Huber C, Rosilio M, Munnich A, Cormier-Daire V. High incidence of SHOX anomalies in individuals with short stature. J Med Genet. 2006; 43: 735-739.
63. Jorge AA, Souza SC, NishiMY,et al.SHOXmutations in idiopathic short stature and Leri-Weill dyschondrosteosis: frequency and phenotypic variability. Clin Endocrinol (Oxf). 2007; 66: 130-135.
64. Rappold G, Blum WF, Shavrikova EP, et al. Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet. 2007; 44: 306-313.
65. Rappold GA, FukamiM,Niesler B, et al. Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab. 2002; 87: 1402-1406.
66. Benito-Sanz S, Barroso E, Heine-Suñer D, et al. Clinical and molecular evaluation of SHOX/PAR1 duplications in Leri-Weill dyschondrosteosis (LWD) and idiopathic short stature (ISS). J Clin Endocrinol Metab. 2011; 96: E404-E412.
67. Benito-Sanz S, Royo JL, Barroso E, et al. Identification of the first recurrent PAR1 deletion in Léri-Weill dyschondrosteosis and idiopathic short stature reveals the presence of a novel SHOX enhancer. J Med Genet. 2012; 49: 442-450.
68. Rosilio M, Huber-Lequesne C, Sapin H, Carel JC, Blum WF, Cormier-Daire V. Genotypes and phenotypes of children with SHOX deficiency in France. J Clin Endocrinol Metab. 2012; 97: E1257-E1265.
69. Moreno-García M, Fernández-Martínez FJ, Barreiro Miranda E. Chromosomal anomalies in patients with short stature. Pediatr Int. 2005; 47: 546-549.
70. Richter-Unruh A, Knauer-Fischer S, Kaspers S, Albrecht B, Gillessen-Kaesbach G, Hauffa BP. Short stature in children with an apparently normal male phenotype can be caused by 45,X/46,XY mosaicism and is susceptible to growth hormone treatment. Eur J Pediatr. 2004; 163: 251-256.
71. Bober MB, Bellus GA, Nikkel SM, et al. Hypochondroplasia. GeneReviews [Internet]. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. Seattle, WA: University of Washington, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK1477/. Published July 15, 1999. Updated September 26, 2013.
72. Song SH, Balce GC, Agashe MV, et al. New proposed clinico-radiologic and molecular criteria in hypochondroplasia: FGFR 3 gene mutations are not the only cause of hypochondroplasia. Am J Med Genet A. 2012; 158A: 2456-2462.
73. Prinster C, Carrera P, Del Maschio M, et al. Comparison of clinicalradiological and molecular findings in hypochondroplasia. Am J Med Genet. 1998; 75: 109-112.
74. Vasques GA, Amano N, Docko AJ, et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. J Clin Endocrinol Metab. 2013; 98: E1636-E1644.
75. Amano N, Mukai T, Ito Y, et al. Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature. J Clin Endocrinol Metab. 2014; 99: E713-E718.
76. Nilsson O, Guo MH, Dunbar N, et al. Short stature, accelerated bone maturation, and early growth cessation due to heterozygous aggrecan mutations [published online April 24, 2014]. J Clin Endocrinol Metab. doi: 10/1210/jc.2014-1332.
77. Wang SR, Carmichael H, Andrew SF, et al. Large-scale pooled nextgeneration sequencing of 1077 genes to identify genetic causes of short stature. J Clin Endocrinol Metab. 2013; 98: E1428-E1437.
78. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010; 126: 746-759.
79. Caliebe J, Broekman S, Boogaard M, et al. IGF1, IGF1R andSHOX mutation analysis in short children born small for gestational age and short children with normal birth size (idiopathic short stature). Horm Res Paediatr. 2012; 77: 250-260.
80. Wit JM, van Duyvenvoorde HA, Scheltinga SA, et al. Genetic analysis of short children with apparent growth hormone insensitivity. Horm Res Paediatr. 2012; 77: 320-333.
81. Clayton P, Bonnemaire M, Dutailly P, et al. Characterizing short stature by insulin-like growth factor axis status and genetic associations: results from the prospective, cross-sectional, epidemiogenetic EPIGROW study. J Clin Endocrinol Metab. 2013; 98: E1122-E1130.
82. Renes JS, Willemsen RH, Wagner A, Finken MJ, Hokken-Koelega AC. Bloom syndrome in short children born small for gestational age: a challenging diagnosis. J Clin Endocrinol Metab. 2013; 98: 3932-3938.
83. Krumm N, Sudmant PH, Ko A, et al. Copy number variation detection and genotyping from exome sequence data. Genome Res. 2012; 22: 1525-1532.
84. Fromer M, Moran JL, Chambert K, et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet. 2012; 91: 597-607.
85. Green RC, Berg JS, Grody WW, et al.ACMGrecommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15: 565-574.
86. Edery P, Marcaillou C, Sahbatou M, et al. Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. Science. 2011; 332: 240-243.
87. He H, Liyanarachchi S, Akagi K, et al. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science. 2011; 332: 238-240.
88. Rauch A, Thiel CT, Schindler D, et al. Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science. 2008; 319: 816-819.
89. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. Asplicing mutation affecting expression of ataxia-Telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet. 2003; 33: 497-501.
90. Ogi T, Walker S, Stiff T, et al. Identification of the first ATRIPdeficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel syndrome. PLoS Genet. 2012; 8: e1002945.
91. Al-Dosari MS, Shaheen R, Colak D, Alkuraya FS. Novel CENPJ mutation causes Seckel syndrome. J Med Genet. 2010; 47: 411-414.
92. Kalay E, Yigit G, Aslan Y, et al. CEP152 is a genome maintenance protein disrupted in Seckel syndrome. Nat Genet. 2011; 43: 23-26.
93. Qvist P, Huertas P, Jimeno S, et al. CtIP mutations cause Seckel and Jawad syndromes. PLoS Genet. 2011; 7: e1002310.
94. Griffith E, Walker S, Martin CA, et al. Mutations in pericentrin cause Seckel syndrome with defective ATR-dependentDNAdamage signaling. Nat Genet. 2008; 40: 232-236.
95. Bicknell LS, Bongers EM, Leitch A, et al. Mutations in the prereplication complex cause Meier-Gorlin syndrome. Nat Genet. 2011; 43: 356-359.
96. Guernsey DL, Matsuoka M, Jiang H, et al. Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin syndrome. Nat Genet. 2011; 43: 360-364.
97. Alatzoglou KS, Dattani MT. Genetic causes and treatment of isolated growth hormone deficiency-An update. Nat Rev Endocrinol. 2010; 6: 562-576.